CD8A and COVID-19: The severity of COVID-19 can be characterized by a marked lymphopenia that affects both CD4+ and CD8+ cells, an increase in neutrophil count, an elevation of acute phase reactants, and a decrease in the monocyte count [25]. Both drugs have been shown to have anti-inflammatory properties, by reducing cytokine production, which would slow down the cytokine storm that deteriorates the condition of COVID-19 patients [5,31].